Insights
Expert analysis across healthcare, life science, pharma, veterinary, social care and digital.

When Babylon Health listed in New York in 2021, the telehealth company was valued at $4.2bn. Within a year later the stock price collapsed and it later filed for bankruptcy. The company’s British assets sold for only £500k. We look at three key lessons for digital health investors.
The most outsourced of all clinical specialties
Operators of special educational needs schools, alternative provision, and education services for children requiring additional support
Specialist providers administering high-acuity treatments such as infusions, biologics and oncology therapies in the home setting
Laboratory networks and pathology operators delivering diagnostic testing to hospitals, clinics, and consumers
Clear strategy on portfolios, pathways and payors
Operators of acute hospitals, day-surgery and outpatient facilities including opthalmic, imaging centres, cancer and radiotherapy clinics, and ambulance services
Staffing agencies, locum platforms and other service providers supplying clinicians and other essential support functions

Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Public health systems including NHS Trusts, Integrated Care Boards and Local Authorities
Authorities and commissioning bodies shaping financial models and system architecture, including NICE and national commissioners here in the UK
Managed care organisations, health insurers and payors financing and reimbursing healthcare

Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Providers of dentistry, optical, audiology, fertility, pharmacy, and wellness services, including fast-growing retail and patient-pay segments
The large originator companies that invest heavily in R&D and drive global therapeutic innovation
Emerging and mid-cap biopharma firms, often venture-backed and focused on advancing new platforms and modalities
Generics, biosimilars and specialty pharma companies focus on cost-competitive supply or niche formulation and complex / hospital-only medicines.
Contract research organisations and site management organisations deliver outsourced trial execution and patient recruitment.
CDMOs support pharma & biotech with process development, scale-up and contract manufacturing.

Radiopharmaceuticals remains a hot topic in 2026, with continued investment from both big and mid-sized pharma, and private equity in the last twelve months. Will Johnson, engagement manager, Lakshiv Dhingra, clinical fellow, and Victor Chua, Partner, at Mansfield Advisors outline key developments and potential asset classes for private equity investors considering the sector.
Developers of next-generation approaches such as cell and gene therapies, oligonucleotide and RNA technologies, genomics & proteomics
Companies supplying laboratory instruments, benchtop equipment, single-use technologies and consumables
Providers of reagents, assays, bioinformatics platforms, and discovery systems
Manufacturers of high-tech medical devices such as cardiac implants, orthopaedics, neuromodulation systems, stents and wound-care products
Firms in imaging, in-vitro diagnostics, digital monitoring and point-of-care testing
Suppliers of surgical tools, hospital equipment and single-use products

Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Veterinary clinic groups, hospitals and diagnostic providers serving companion animals and pets
Companies producing medicines, vaccines, and feed additives that improve health and productivity across pets and livestock

Shows where opportunities exist and their scale, through structured market analysis.
Guides entry into new geographies, supported by risk–benefit assessment and route-to-market planning.
Strengthens how you reach and engage customers, drawing on segmentation and positioning tools.
Clarifies how to stand out and defend share, using competitor benchmarking and strategy frameworks.
Examines the durability of income, using customer, contract, and market analysis.
Examines the durability of income, using customer, contract, and market analysis.
Identifies and quantifies growth potential, supported by market sizing and forecast models.
Tests how sustainable current prices are, informed by customer feedback and market evidence.
Evaluates adoption potential and reimbursement prospects through structured evidence review.
Compares strengths and weaknesses against peers, using structured benchmarking.
Pinpoints the actions that drive growth and efficiency, aligned to investor and board priorities.
Identifies the real causes of missed targets, using root-cause and capability analysis.
Tests whether the portfolio is strategically coherent, supported by capital allocation and fit analysis.
Measures how performance compares locally, using peer benchmarks and market data.
Examines how well the business model matches market dynamics, using practical fit-for-purpose tests.
Develops clear, evidence-based stories for governance and stakeholder communication.
Defines how to reset direction, based on market trends and competitive realities.
Lays out the path to customers, informed by adoption patterns and channel economics.
Builds approaches that balance payer, provider, and patient value, grounded in reimbursement rules.
Shapes collaborations that expand access, supported by practical partnership structures.
Aligns teams and structures with strategy, using operating-model and governance design.
Gauges readiness for change, using staged capability assessments.
Builds digital enablers for outcomes-based health, guided by value-based care frameworks.
Designs digitally enabled health systems, informed by system-level commissioning models.
Connects platforms and data, supported by interoperability and system architecture.
Directs capital to the initiatives with the greatest impact, using portfolio prioritisation tools.




Expert analysis across healthcare, life science, pharma, veterinary, social care and digital.
An error has occurred, please try again later.An error has occurred, please try again later.









